Investigating CAR-T Efficacy Limitations in Chronic Lymphocytic Leukemia
Efficacy limitations of CAR-T therapy in CLL may not be due to defects in the CAR-T product, but rather, to characteristics of the tumor cells.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Outpatient CAR-T Therapy May Offer Cost Savings, but More Data Are Needed
Administering CAR-T cell therapy in the outpatient community setting is estimated to save more than $30,000 per patient. -
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing. -
Clotting and COVID: New Guidelines in the Works to Treat Coagulopathies in Patients With COVID-19
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population. -
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
HEMATOLOGIC CANCER NEWS
Novel Triple Therapy With First-in-Class Selinexor Improves Outcomes in Multiple Myeloma
Head-to-Head: Zanubrutinib vs Ibrutinib in Waldenström Macroglobulinemia
Durable Long-Term Responses in B-cell Lymphoma and Chronic Lymphocytic Leukemia After Anti-CD19 CAR T-Cell Therapy
Close Monitoring, Full-Time Caregiver Recommended for 30 Days After CAR-T Therapy
Pembrolizumab Superior to Brentuximab Vedotin for Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
